PTEN and cancer: Preclinically, two additional p110β-specific inhibitors KIN-193 (AZD6482) and SAR260301 have also shown efficacy in various murine PTEN-deficient cancer models in vivo [172,173], further supporting the therapeutic strategy of targeting p110β in cancers with PTEN loss.